Regulatory scientific significance of Japan’s ADR relief system

Toshi TOMINGA, Ph.D.
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA)
Disclaimer

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners.
Japan’s ADR Relief System

1. Streamlined rescue for ADR sufferers
2. To promote safer use of medicines
3. To ease societal apprehension about new drugs and to help innovation
Coverage of Japan’s Relief System

- Adverse Drug Reactions (ADRs) and Infections
- drugs, biologics, and regenerative medicine products (e.g. cellular, tissue, and gene therapies),
- prescription and over-the-counter (OTC) drugs, but not anti-cancer agents and immunosuppressants.
- known and unknown ADRs etc. necessitating hospitalization or graver.

Relief Fund

- Fund for Relief Services for Adverse Drug Reactions is maintained through mandatory annual contributions from the marketing approval holders.
Rationale of the Relief System

• There are unpreventable drug-related harms.

• In response to such drug-related harms, the manufacturer of the relevant medicine may not be held liable under generally-applicable product liability doctrine.

• Even in cases where civil liability may be pursued, sufficiently proving the necessary element of causality and fault in civil litigation is generally very difficult and places tremendous time, mental, physical, and financial burdens on victims.

• There is a societal obligation to provide relief to victims of drug-related harms who are unable to obtain relief from other sources. Or, because no individual party can bear full responsibility for harms caused by unpreventable drug-related harms, it becomes the duty of society as a whole to provide this relief to victims.

• Because drug manufacturers are responsible for ensuring as much as possible the safety and efficacy of the products, they should bear primary responsibility for financing relief payments.
Criteria for compensation eligibility

A) reasonably plausible causal relationship b/w the drug & the adverse event
   a. Expert staff at PMDA and MHLW primarily examine the chronology of the suspected medication use, and compare this to the timing of symptom onset
   b. Unless the possibility of a causal relationship is wholly eliminated, the benefit of the doubt is afforded to the claimant.

B) the use(s) of the medication associated with the adverse event were “proper”.
   a. The drug must have been administered according to the approved dosage and other usage instructions (e.g. instructions requiring that the patient undergo periodic blood tests, etc.), with some allowance for deviation in the light of current medical science.
Pathway with Product Liability Act needs;

(a) the existence of a defect in a manufactured or processed good
(b) actual harm suffered
(c) causation

– But no need to prove negligence.

However

– Manufacturers can avoid liability if they can prove that discovering the relevant defect was impossible at the time of delivery to the user.

– information-gathering activities in Japan are far more restricted than in USA.
Relief Service as public administration

Sufferers of Adverse Events → Claim → PMDA → Subsidy for Admin. Cost

PMDA → Request Judgment → Consult → MHLW

MHLW → Advisory Council

MHLW → Notice Judgment

MHLW → Consult

Manufacturers of Drugs and Biologics

Hospitals, Clinics → Additional info.
Inevitable “trial and error” in establishing a drug’s usage

Even with the drug’s usage established, known ADRs do occur

Target population

Inevitable ADR cases as cost to establish usage

Society, drug use, and ADR as cost

Efficacy

Safety (ADR)

B
enefit

R
isk

1st line

2nd

3rd

Inevitable ADR cases as cost to maintain on the market
Japan’s conditional & time-limited authorization for cellular, tissue, and gene therapy products (regenerative medicine products).

E.g. Autologous skeletal myoblast

Relief Coverage from the First Approval
Innovative products are often with greater uncertainties when marketed

- Coverage by the Relief System should encourage use of drugs with reasonable caution and without excessive fear.
- Coverage decreases risk of product liability litigation for manufacturers of innovative products

Coverage is expected to progress a drug’s lifecycle, especially in post-market evidence acquisition (e.g. for adaptive pathway) and promote innovation.
Contribution to Safety Measures

1. Relief cases are also reportable in spontaneous ADR reporting. In theory PMDA receives duplicative reports/claims.

2. Relief claims frequently contain more information than spontaneous reports, especially the claimant’s medical history long before the occurrence of the event.

3. MHLW/PMDA’s Relief Service Offices and Post-market Safety Offices combine ADR information from multiple sources and formulate safety measures.

4. Viewpoint: signal detection from multiple spontaneous reports vs. causal relationship in the claimant.

5. The condition of “proper use” implies that a doctor’s failure to take suitable precautionary measures could cost a claimant’s chance of financial compensation. This encourages health care professionals’ compliance.
Example 1: Adefovil pivoxil (anti Hepatitis B) & Fanconi Syndrome

Fanconi Syndrome

- Muscle Weakness
- Joint Pain
- Renal Damage (on re-absorption of Phosphate, etc.)

Avg. 18 months

Bone Fracture

Patient’s History in Relief Claim data

Labelling Change (2012)
- Warned Possible course of events from hypophosphatemia to osteomalacia and bone fracture
- Mandated observation of serum phosphate and alkaline phosphate
Example 2: Thiamazole and Agranulocytosis

PMDA Alert for Proper Use of Drugs (2011)

1. Strongly recommended
   - Periodic blood test (esp. once/2 weeks, first 2 months)
   - Symptoms including pharynx pain, etc.
2. Warned the doctors
   - Without blood tests, your patients are NOT eligible for Relief.
The Effect of PMDA Alert for Proper Use of Drugs (2011)

Number of Judged Cases

PMDA Alert for Proper Use of Drugs (Dec. 2011)

Proper Use

Improper Use

Year (1Q~4Q)

2007

2008

2009

2010

2011

2012

2013

2014

0

5

10

Feb. 2004 DHCP Letter

Nov. 2007 Warning

Recommended timing of leukocyte counts

Start

1 month

2 months

Check differential leukocyte count once every 2 weeks.

Perform periodic blood tests.

which were reported to the PMDA between February 2004 and August 2011.
Special Thanks to;
Seiko Miyazaki, Ph. D., Yukio Oniyama, M.S., and Ariel D. Weber J.D., M.S.